Net decreases in prevalence seen across age groups, with largest relative reduction for young adults aged 18 to 29 years.
Pivotal adult trial data support planned BLA submission for Vaxcyte's investigational 31-valent pneumococcal conjugate vaccine candidate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results